These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21035943)

  • 1. Is prostate cancer screening bad or good? Summary of a debate at the innovation in urology meeting, September 17-19, 2010, Milan, Italy.
    Roobol MJ
    Eur Urol; 2011 Mar; 59(3):359-62. PubMed ID: 21035943
    [No Abstract]   [Full Text] [Related]  

  • 2. Is population screening for prostate cancer good or bad?
    Clarke NW
    Eur Urol; 2011 Mar; 59(3):363-4. PubMed ID: 21167635
    [No Abstract]   [Full Text] [Related]  

  • 3. Screening for prostate cancer: practical analysis of the ERSPC [corrected] and PLCO trials.
    Djavan B
    Eur Urol; 2011 Mar; 59(3):365-9. PubMed ID: 21159418
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
    Colli JL; Amling CL
    Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening.
    Bigby M
    Arch Dermatol; 2010 Mar; 146(3):322-4. PubMed ID: 20231506
    [No Abstract]   [Full Text] [Related]  

  • 6. New trial data do not end the PSA screening debate.
    Vastag B
    J Natl Cancer Inst; 2009 Jun; 101(12):844-5. PubMed ID: 19509364
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-cancer screening.
    Catalona WJ
    N Engl J Med; 2009 Jul; 361(2):202; author reply 204-5. PubMed ID: 19587348
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of publication of US and European prostate cancer screening trials on PSA testing practices.
    Zeliadt SB; Hoffman RM; Etzioni R; Gore JL; Kessler LG; Lin DW
    J Natl Cancer Inst; 2011 Mar; 103(6):520-3. PubMed ID: 21357307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy vs effectiveness in prostate-specific antigen screening.
    Albertsen PC
    J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
    [No Abstract]   [Full Text] [Related]  

  • 11. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer screening: more harm than good?
    Lefevre ML
    Am Fam Physician; 1998 Aug; 58(2):432-8. PubMed ID: 9713397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An argument against routine prostate cancer screening.
    Hoffman RM
    Arch Intern Med; 2003 Mar; 163(6):663-5; discussion 665-6. PubMed ID: 12639196
    [No Abstract]   [Full Text] [Related]  

  • 14. [Epidemiology of prostatic cancer].
    Harvei S
    Tidsskr Nor Laegeforen; 1999 Oct; 119(24):3589-94. PubMed ID: 10563177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Descriptive epidemiology of prostate cancer in Japan and Western countries].
    Wakai K
    Nihon Rinsho; 2005 Feb; 63(2):207-12. PubMed ID: 15714967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 17. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for prostate cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 Mar; 103(3):107-10; discussion 111. PubMed ID: 12626949
    [No Abstract]   [Full Text] [Related]  

  • 19. Screening for prostate cancer: a comparison of urologists and primary care physicians.
    McKnight JT; Tietze PH; Adcock BB; Maxwell AJ; Smith WO; Nagy MC
    South Med J; 1996 Sep; 89(9):885-8. PubMed ID: 8790311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer and prostate-specific antigen: facts, figures and commentary.
    Chambers DC
    J Insur Med; 1993; 25(3):336-40. PubMed ID: 10146433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.